Xellia Pharmaceuticals Expands Anti-Infective Product Manufacturing
Xellia Pharmaceuticals invests US$25 million in its Copenhagen, Denmark site to expand sterile manufacturing of products for treating antimicrobial resistant infections.
Xellia Pharmaceuticals held a ground-breaking ceremony for a new US$25-million expansion at its Copenhagen, Denmark site, the company announced in a Oct. 11, 2017 press release. The company has begun construction of a multi-story building that will house sterile manufacturing equipment and containment solutions in a purpose-built environment for manufacturing products for treating antimicrobial resistant infections.
This site also houses Xellia’s headquarters and is the company’s largest product manufacturing plant. It is responsible for manufacturing, stability testing, and packaging of both sterile APIs and finished dosage forms for anti-infectives such as vancomycin and colistimethate sodium. This upgrade in facilities will ensure that the company is able to continue to provide a reliable supply of injectable anti-infective critical care medicines.
Source: Xellia
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
